Mallinckrodt (MNK) Beats On Q1 Earnings & Sales, Raises View
Zacks Investment Research | May 08, 2019 04:00AM ET
Mallinckrodt Public Limited Company (NYSE:MNK) reported better-than-expected results for the first quarter of 2019, led by strong performance of hospital products. The company also raised its guidance.
The company reported adjusted earnings of $1.94 per share in the quarter, up from the year-ago quarter’s $1.62. Also, the bottom line beat the Zacks Consensus Estimate of $1.73.
Net sales in the quarter came in at $790.6 million, up 4.7% year over year. The figure surpassed the Zacks Consensus Estimate of $771.5 million.
Mallinckrodt’s stock has gained 2% in the year so far against the industry ’s growth of 8.8%.
Quarter in Detail
The company now operates two reportable segments aligned to the previously-announced separation — the Specialty Brands and the Specialty Generics (includes Amitiza).
Specialty brand sales came in at $547.3 million, down 0.4% year over year.
Acthar, Mallinckrodt’s largest product, generated sales of $223.9 million, down 8.2% due to reset process impacting returning patients.
Inomax, the company’s second-largest product, generated sales of $151.1 million, up 8.1% driven by continued and consistent demand and contract renewals. Ofirmev sales increased 16.6% year over year to $95.6 million, owing to strong demand and order timing.
Sales of the Therakos immunology platform were $61.8 million, up 7.7%.
Specialty Generics and Amitiza sales amounted to $243.3 million, up 17.6%. Amitiza posted net sales of $53.0 million, while Specialty Generics products net sales returned to growth with $190.3 million, up 3.5% driven by recapture of market share.
Adjusted selling, general and administrative expenses in the quarter were $211.4 million, up from $207.9 million in the year-ago quarter. Meanwhile, research and development expenses increased 4% to $85.3 million.
During the quarter, the company reduced total debt by $263.5 million.
Guidance Update
Total sales for Specialty Brands are expected to increase 1-4%. Total sales for Specialty Generics and Amitiza are now expected to increase 2-5% (previous guidance: 1-4% ). Earnings per share are now projected to be $8.30-$8.60, up from the previous projection of $8.10-$8.40.
Our Take
Impressive results in the first quarter bode well for Mallinckrodt. The hospital portfolio looks solid as Ofirmev and Inomax gained market share and the troubled generics segment has returned to growth.
Get The News You Want
This year is expected to be a transformative one for Mallinckrodt, as it strives to revive its portfolio/pipeline. In December 2018, the company announced that it intends to spin-off the Specialty Generics/Active Pharmaceutical Ingredients business along with Amitiza into a new company. The separation is expected in the second half of the year. We expect investors to focus on the same.
Zacks Rank & Key Picks
Mallinckrodt carries a Zacks Rank #3 (Hold).
Some better-ranked stocks are Bristol-Myers Squibb Co. (NYSE:BMY) , Roche (OTC:RHHBY) and Ligand Pharmaceuticals Inc. (NASDAQ:LGND) . While the first two sport a Zacks Rank #2 (Buy), Ligand carries a Zacks Rank #1 (Strong Buy). You can see .
Bristol-Myers’ earnings per share estimates have increased from $4.76 to $4.93 for 2020 in the past 60 days.
Roche’s earnings per share estimates have increased from $2.35 to $2.40 for 2019 in the past 60 days.
Ligand’s earnings per share estimates have increased from $28.72 to $29.14 for 2019 and from 24 cents to 69 cents for 2020 in the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.